---
title: "Esperion Therapeutics: Strong 2025 Execution, Expanding Cardiometabolic Platform, and Vision 2040 Underpin Buy Rating"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278583191.md"
description: "Joseph Pantginis from H.C. Wainwright has maintained a Buy rating on Esperion Therapeutics with a price target of $16.00, citing strong 2025 execution and growth potential. U.S. sales of NEXLETOL/NEXLIZET have increased significantly, supported by prescription trends and market access. The company's expanding cardiometabolic platform and long-term strategy, Vision 2040, aim to create a blockbuster franchise. The Corstasis acquisition and advancements in their pipeline reinforce Pantginis's positive outlook. Needham also maintains a Buy rating with a $5.00 price target."
datetime: "2026-03-10T15:35:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278583191.md)
  - [en](https://longbridge.com/en/news/278583191.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278583191.md)
---

# Esperion Therapeutics: Strong 2025 Execution, Expanding Cardiometabolic Platform, and Vision 2040 Underpin Buy Rating

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Esperion, with a price target of $16.00.

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Joseph Pantginis has given his Buy rating due to a combination of factors including Esperion’s strong 2025 execution and positioning for further growth. He highlights that U.S. sales of NEXLETOL/NEXLIZET rose sharply year over year, supported by robust prescription trends and broadening market access, while real-world data confirm durable LDL-C reductions that should underpin wider clinical adoption.

Pantginis also points to the company’s expanding cardiometabolic platform and long-term “Vision 2040” strategy, which aim to build a multiproduct, blockbuster-scale franchise. The Corstasis acquisition, advancement of triple-combination BDA programs, and progress on the next-generation ACLY inhibitor ESP-2001 together reinforce his view that Esperion has meaningful strategic momentum and a pipeline capable of sustaining value creation beyond the near term.

In another report released on March 3, Needham also maintained a Buy rating on the stock with a $5.00 price target.

### Related Stocks

- [ESPR.US](https://longbridge.com/en/quote/ESPR.US.md)

## Related News & Research

- [Esperion Therapeutics Highlights 38% Revenue Growth, Enbumyst Launch Plan at Needham Conference](https://longbridge.com/en/news/282600951.md)
- [Esperion Completes Corstasis Acquisition, Expands Cardiovascular Portfolio](https://longbridge.com/en/news/281578871.md)
- [China Sees Spike in AED Orders, but Experts Say Training Is the Real Challenge](https://longbridge.com/en/news/282526367.md)
- [Move Over Novo Nordisk - This Small Company Study Flags Edge In Fatty Liver Drug](https://longbridge.com/en/news/282724683.md)
- [Protaryx Medical Receives FDA 510(k) Clearance for Its Breakthrough Transseptal Puncture Device](https://longbridge.com/en/news/282576123.md)